title: Targeted therapies in rheumatoid arthritis: Focus on rituximab.
abstract: B-cell depletion is a new strategy for treating patients with rheumatoid arthritis (RA). In the past years, several studies have proven the efficacy of anti-CD20 mediated B-cell depletion with rituximab (Mabthera((R))) in RA patients who failed TNF-blocking therapy. The important role of B-cells in the pathogenesis of RA is deducted from the specific detection of autoantibodies in RA and infiltration of B-cells and plasma cells in inflamed synovium. Pharmacological studies in RA patients treated with rituximab showed that half-life was approximately 3 weeks leading to a 6- to 8-month period of B-cell depletion in peripheral blood. Rituximab treatment led to significant improvements in disease activity of RA patients and the current review summarizes the results from phase III, randomized clinical trials that have been performed. Lastly, data on safety and quality of life are summarized. Although relatively low numbers of RA patients have been treated and long-term data are lacking, current data thus far suggest a relatively good safety profile for rituximab. Future studies will need to focus on predicting responsiveness to rituximab, investigating efficacy of re-treatment with rituximab and extending data on safety and patient-focused outcomes.
authors.affiliation: Department of Rheumatology, Leiden University Medical Center, The Netherlands.
authors.forename: Y K
authors.initials: YK
authors.lastname: Teng
authors.forename: T W
authors.initials: TW
authors.lastname: Huizinga
authors.forename: J M
authors.initials: JM
authors.lastname: van Laar
references.citation: Crit Rev Oncol Hematol. 2001 Oct;40(1):3-16
references.pmid: 11578912
references.citation: Arthritis Rheum. 2001 Apr;44(4):754-60
references.pmid: 11315914
references.citation: Arthritis Rheum. 1994 Nov;37(11):1647-55
references.pmid: 7980676
references.citation: Expert Rev Anticancer Ther. 2006 Oct;6(10):1341-53
references.pmid: 17069520
references.citation: J Immunol. 2006 Jul 1;177(1):362-71
references.pmid: 16785532
references.citation: Proc Soc Exp Biol Med. 1948 May;68(1):1-6
references.pmid: 18863659
references.citation: N Engl J Med. 2002 Jan 24;346(4):235-42
references.pmid: 11807147
references.citation: Biochemistry. 2005 Nov 22;44(46):15150-8
references.pmid: 16285718
references.citation: Curr Dir Autoimmun. 2005;8:175-92
references.pmid: 15564721
references.citation: N Engl J Med. 2004 Jun 17;350(25):2572-81
references.pmid: 15201414
references.citation: Arthritis Rheum. 2004 Jun;50(6):1897-908
references.pmid: 15188366
references.citation: Ann Rheum Dis. 2007 Oct;66(10):1356-62
references.pmid: 17293364
references.citation: N Engl J Med. 2000 Nov 30;343(22):1586-93
references.pmid: 11096165
references.citation: Bone Marrow Transplant. 1992 Jun;9(6):395-408
references.pmid: 1628122
references.citation: Ann Intern Med. 2007 Mar 20;146(6):406-15
references.pmid: 17371885
references.citation: N Engl J Med. 1999 Jan 28;340(4):253-9
references.pmid: 9920948
references.citation: Ann Rheum Dis. 2004 Sep;63(9):1085-9
references.pmid: 15308517
references.citation: Arthritis Rheum. 2008 Feb;58(2):634; author reply 634
references.pmid: 18240246
references.citation: Rheumatology (Oxford). 2007 Jan;46(1):29-36
references.pmid: 16735454
references.citation: Arthritis Rheum. 2006 Aug;54(8):2356-67
references.pmid: 16868991
references.citation: Arthritis Rheum. 2003 Jan;48(1):35-45
references.pmid: 12528101
references.citation: Oncogene. 2003 Oct 20;22(47):7359-68
references.pmid: 14576843
references.citation: Rheum Dis Clin North Am. 2004 May;30(2):393-403, viii
references.pmid: 15172048
references.citation: Arthritis Res Ther. 2005;7(3):R569-80
references.pmid: 15899044
references.citation: N Engl J Med. 2004 Jun 17;350(25):2546-8
references.pmid: 15201410
references.citation: J Rheumatol. 2002 Aug;29(8):1631-8
references.pmid: 12180721
references.citation: J Clin Pharmacol. 2005 Jul;45(7):792-801
references.pmid: 15951469
references.citation: Arthritis Res Ther. 2004;6(3):107-11
references.pmid: 15142259
references.citation: Nat Immunol. 2001 Sep;2(9):764-6
references.pmid: 11526379
references.citation: Anticancer Drugs. 2002 Nov;13 Suppl 2:S3-10
references.pmid: 12710585
references.citation: Semin Oncol. 2002 Feb;29(1S2):2-9
references.pmid: 28140087
references.citation: Ann Rheum Dis. 2005 Oct;64(10):1510-2
references.pmid: 15800005
references.citation: Rheumatology (Oxford). 2000 Sep;39(9):975-81
references.pmid: 10986302
references.citation: Ann Rheum Dis. 2004 Oct;63(10):1218-21
references.pmid: 15361374
references.citation: Curr Opin Rheumatol. 2003 May;15(3):246-52
references.pmid: 12707577
references.citation: Arthritis Rheum. 2007 Mar;56(3):772-8
references.pmid: 17328049
references.citation: Ann Rheum Dis. 2005 Oct;64(10):1516-7
references.pmid: 16162906
references.citation: Ann Rheum Dis. 2005 Apr;64(4):537-43
references.pmid: 15769913
references.citation: Arthritis Rheum. 2006 Sep;54(9):2793-806
references.pmid: 16947627
references.citation: Ann Rheum Dis. 2002 Oct;61(10):883-8
references.pmid: 12228157
references.citation: Arthritis Rheum. 2006 May;54(5):1390-400
references.pmid: 16649186
references.citation: Rheumatology (Oxford). 2001 Feb;40(2):205-11
references.pmid: 11257159
references.citation: Lancet. 1999 Dec 4;354(9194):1932-9
references.pmid: 10622295
references.citation: Ther Apher. 2001 Apr;5(2):79-83
references.pmid: 11354303
references.citation: J Rheumatol. 2004 Mar;31(3):482-8
references.pmid: 14994391
references.citation: Arthritis Rheum. 2006 Feb;54(2):613-20
references.pmid: 16447239
references.citation: Science. 1957 Jul 26;126(3265):162-3
references.pmid: 13442661
references.citation: Arthritis Rheum. 2006 Aug;54(8):2377-86
references.pmid: 16869000
references.citation: Intern Med. 2005 Nov;44(11):1122-6
references.pmid: 16357447